pubmed-article:12870806 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C0005779 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C0015502 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C1623038 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C0149684 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C1552302 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C1552291 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
pubmed-article:12870806 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
pubmed-article:12870806 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:12870806 | pubmed:dateCreated | 2003-7-21 | lld:pubmed |
pubmed-article:12870806 | pubmed:abstractText | The prevalence of colonic polyps in patients with cirrhosis appears to be higher than that of the general population. The current practice for a polypectomy in a coagulopathic cirrhotic patient involves the reversal of the coagulopathy using fresh frozen plasma (FFP) prior to the polypectomy, usually at a second colonoscopy. The use of FFP is associated with many problems, particularly that of volume overload. Here we report four cases with advanced cirrhosis and severe coagulopathy that underwent polypectomies by snare cautery after an intravenous bolus infusion of recombinant human factor VIIa (rhFVIIa). The dose used was 120 microg/kg, which provided normalization of the coagulation parameters for 10-16 hr. The immediate use of rhFVIIa reduced the utilization of resources and enabled the performance of the polypectomies at the initial colonoscopy. No postpolypectomy bleeding was noted. The high cost of the drug is the only obstacle to a wider use of rhFVIIa for this purpose. The cost of the drug, however, is offset substantially by the cost of hospitalization for the administration of FFP, the cost of a second colonoscopy, and the charges associated with a second utilization of the endoscopy suite. | lld:pubmed |
pubmed-article:12870806 | pubmed:language | eng | lld:pubmed |
pubmed-article:12870806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12870806 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:12870806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12870806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12870806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12870806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12870806 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12870806 | pubmed:month | Jul | lld:pubmed |
pubmed-article:12870806 | pubmed:issn | 0163-2116 | lld:pubmed |
pubmed-article:12870806 | pubmed:author | pubmed-author:Van... | lld:pubmed |
pubmed-article:12870806 | pubmed:author | pubmed-author:MehtaKapilK | lld:pubmed |
pubmed-article:12870806 | pubmed:author | pubmed-author:AnantharajuAb... | lld:pubmed |
pubmed-article:12870806 | pubmed:author | pubmed-author:MindikogluAys... | lld:pubmed |
pubmed-article:12870806 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12870806 | pubmed:volume | 48 | lld:pubmed |
pubmed-article:12870806 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12870806 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12870806 | pubmed:pagination | 1414-24 | lld:pubmed |
pubmed-article:12870806 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:meshHeading | pubmed-meshheading:12870806... | lld:pubmed |
pubmed-article:12870806 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12870806 | pubmed:articleTitle | Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. | lld:pubmed |
pubmed-article:12870806 | pubmed:affiliation | Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA. | lld:pubmed |
pubmed-article:12870806 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12870806 | pubmed:publicationType | Case Reports | lld:pubmed |